Clinical Trial

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 14, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Investigators intend to combine low-dose hypersensitivity with high-dose immunopotentiation effect, and use super-hyperfractionation pulse radiotherapy, which is expected to achieve the effect of in situ vaccine that can enhance tumor killing, protect normal tissues, reduce immune cell damage and enhance tumor immunogenicity at the same time, and play a stronger immunopotentiation effect in combined immunotherapy. Thereby inducing a stronger abscopal effect of radiotherapy.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-02-22; most recent amendment 2025-07-11.
Trial Details
NCT Number NCT05754203
Lead Sponsor Xinqiao Hospital of Chongqing
Conditions Lung Cancer, Immune Checkpoint Inhibitor, Radiotherapy
Enrollment 40 participants
Start Date 2023-08-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-07-14